AGL - agilon health, inc. Последние новости | Finranks

12.08.2026

Has Agilon Health (AGL) Outpaced Other Medical Stocks This Year?

Here is how Agilon Health (AGL) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.

07.08.2026

agilon health: The Q2 Inflection Is Real

agilon Health delivered a strong Q2 2026 with revenue of $1.49B, a $250M YoY medical margin swing, and raised FY26 guidance across all key metrics. AGL's operational turnaround is supported by improved cost trends, enhanced data pipelines, and clinical pathway execution, notably reducing inpatient first-diagnosis rates from 25% to under 5%. Balance sheet strength is evident with over $220M net cash, while disciplined membership management supports ongoing profitability.

06.08.2026

agilon health, inc. (AGL) Q2 2026 Earnings Call Transcript

06.08.2026

Agilon Health Q2 Earnings Call Highlights

Agilon Health NYSE: AGL reported second-quarter results that exceeded its guidance for medical margin and adjusted EBITDA, citing stronger risk-adjustment revenue, favorable medical-cost development and progress in its clinical and quality initiatives. The company also raised its full-year 2026 outlook.

06.08.2026

Agilon Health (AGL) Tops Q2 Earnings and Revenue Estimates

Agilon Health (AGL) came out with quarterly earnings of $1.04 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to a loss of $6.25 per share a year ago.

06.08.2026

Agilon (AGL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Agilon (AGL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

05.08.2026

agilon health Reports Second Quarter 2026 Results

WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced results for the second quarter ended June 30, 2026. In addition, the company increased full-year 2026 guidance for total revenues, medical margin, and Adjusted EBITDA. “Our second quarter results exceeded our expectations, demonstrating meaningful progress across agilon's strategic initiatives and reinforcing our confidence i.

Видео

No Data

There is no data to display

Повышения / Понижения рейтинга

Тикер	Фирма	Изменение рейтинга	Целевая цена	Дата
AGL	Citigroup	Neutral	undefined >> $115	August 11th 2026

Пресс-релизы

05.08.2026

agilon health, inc. (AGL)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

agilon health, inc. (AGL)